Knight Therapeutics Inc
TSX:GUD
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5.11
6.2
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CAD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Knight Therapeutics Inc
Net Income
Knight Therapeutics Inc
Net Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Net Income
-CA$30.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Net Income
-$217m
|
CAGR 3-Years
43%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Sundial Growers Inc
NASDAQ:SNDL
|
Net Income
-CA$176.6m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Net Income
-$58m
|
CAGR 3-Years
27%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Net Income
-$97.8m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-144%
|
CAGR 10-Years
-110%
|
|
|
C
|
Curaleaf Holdings Inc
CNSX:CURA
|
Net Income
-$450.5m
|
CAGR 3-Years
-104%
|
CAGR 5-Years
-315%
|
CAGR 10-Years
N/A
|
|
Knight Therapeutics Inc
Glance View
Knight Therapeutics Inc engages in acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. The company is headquartered in Montreal, Quebec and currently employs 660 full-time employees. The company went IPO on 2014-02-28. The firm's principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. The Company’s products include BIJUVA Estradiol and Progesterone capsule, IMVEXXY Estradiol vaginal inserts, IBSRELA Tenapanor tablets, TRELSTAR Prostate Triptorelin, TRELSTAR Endometriosis Triptorelin, ILUVIEN Fluocinolone acetonide, Nerlynx Neratinib Tablets, Nerlynx Patient Checklist, Nerlynx Prescriber Checklist, Burinex Bumetanide, Probuphine Buprenorphine implant, Movantik Naloxegol and Neuragen. The company owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical company. Its subsidiaries operates under United Medical, Biotoscana Farma and Laboratorio LKM.
See Also
What is Knight Therapeutics Inc's Net Income?
Net Income
-30.7m
CAD
Based on the financial report for Sep 30, 2024, Knight Therapeutics Inc's Net Income amounts to -30.7m CAD.
What is Knight Therapeutics Inc's Net Income growth rate?
Net Income CAGR 1Y
-299%
Over the last year, the Net Income growth was -299%.
You don't have any saved screeners yet
